Related Experiment Video
Updated: Jun 17, 2025
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Neuroprotective Effect of Clemastine Improved Oligodendrocyte Proliferation through the MAPK/ERK Pathway in a
Maria E Bernis1,2, Charlotte Hakvoort1,2, Efe Nacarkucuk1,2
1Neonatologie und Pädiatrische Intensivmedizin, Eltern-Kind-Zentrum, Universitätsklinikum Bonn, 53127 Bonn, Germany.
Insights
Clemastine shows neuroprotective effects against white matter injury in a neonatal hypoxic-ischemic encephalopathy rat model. This drug promotes oligodendrocyte proliferation, offering potential for treating this condition.
Area of Science:
- Neuroscience
- Developmental Neuroscience
- Pharmacology
Background:
- Neonatal hypoxic-ischemic encephalopathy (HIE) is a leading cause of long-term neurological disability in newborns.
- White matter injury is a primary contributor to cerebral palsy following HIE.
- Targeting myelination and oligodendrocyte precursor cell (OPC) proliferation offers a therapeutic strategy for HIE.
Purpose of the Study:
- To investigate the neuroprotective potential of clemastine in a rat model of neonatal HIE.
- To evaluate clemastine's effects on white matter integrity and oligodendrogenesis.
- To explore the underlying mechanistic pathways, including the MAPK/ERK pathway.
Main Methods:
- A rat model of neonatal hypoxic-ischemic brain injury was established.
- Animals received daily intraperitoneal injections of clemastine (10 mg/kg) or vehicle for six consecutive days.
- Histological analysis was performed to assess white matter loss and quantify Olig2+ cells.
Main Results:
- Clemastine treatment significantly reduced white matter loss compared to vehicle control.
- A significant increase in the number of Olig2+ cells, indicating enhanced oligodendrogenesis, was observed in clemastine-treated animals.
- The MAPK/ERK pathway was identified as a potential mediator of clemastine's neuroprotective effects.
Conclusions:
- Clemastine demonstrates significant neuroprotective effects in a neonatal HIE rat model.
- The drug promotes oligodendrogenesis and preserves white matter integrity.
- Clemastine represents a promising therapeutic candidate for treating white matter injury associated with HIE.
Abstract:
Neonatal hypoxic-ischemic encephalopathy is the most common cause of long-term disability in term neonates, and white matter injury is the primary cause of cerebral palsy. Therapies that focus on the neuroprotection of myelination and oligodendrocyte proliferation could potentially ameliorate long-lasting neurological impairments after hypoxic-ischemic encephalopathy. Clemastine, a histamine H1 antagonist, has been shown to exert neuroprotective effects in multiple sclerosis and spinal cord injury by promoting oligodendrogenesis and re-myelination. In this study, we demonstrated the neuroprotective effects of clemastine in our rat model of neonatal hypoxic-ischemic brain injury. Animals received a single intraperitoneal injection of either vehicle or clemastine (10 mg/kg) for 6 consecutive days. Our results showed a significant reduction in white matter loss after treatment, with a clear effect of clemastine on oligodendrocytes, showing a significant increase in the number of Olig2+ cells. We characterized the MAPK/ERK pathway as a potential mechanistic pathway underlying the neuroprotective effects of clemastine. Altogether, our results demonstrate that clemastine is a potential compound for the treatment of hypoxic-ischemic encephalopathy, with a clear neuroprotective effect on white matter injury by promoting oligodendrogenesis.
